You just read:

Regeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for Review for Diabetic Macular Edema Indication

News provided by

Regeneron Pharmaceuticals, Inc.

Dec 18, 2013, 07:30 ET